By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Novartis opens global production facility for innovative retina drug in Tyrol

Novartis produces new retina grug in Tyrol © Novartis

The Swiss pharmaceutical company Novartis recently announced that it launched a global production facility for innovative retina drug ingredients at its site in Kundl, Tyrol. The company invested a total of about USD 30 million (or approx. EUR 27.4 million) for this purpose. The production of active pharmaceutical ingredients will take place simultaneously in both Switzerland and Tyrol. The plant in Kundl will be expanded by the beginning of 2021 to gradually service as the exclusive production centre and will also assume sole responsibility for global deliveries. "This substance is a humanised single-chain antibody fragment whose production requires top-class know-how. In this way, Novartis in Austria is once again demonstrating its innovative strength", explained Michael Kocher, Novartis Country President, and Mario Riesner, Plant Manager in Kundl.

The substance will be used within the context of a therapy for a widespread disease of the retina (wet age-related macular degeneration) and was approved by European authorities in February 2020. A team of up to 40 specialists of the Novartis Technical Operations Network is working in three shifts Tyrol to manufacture the antibody fragment in line with the highest quality and safety standards. "The investments in the global production of this new substance underline the central role played by the Austrian sites in the global Novartis network. It is a strong commitment, and we are convinced that we, the Austrian team here, will succeed in attracting further innovative drugs and their production to Tyrol", said Kocher and Riesner.

From a medical perspective, the experts expect a strong level of effectiveness of the substance in treating the areas of the retina affected by the pathological wetness. This was shown in the pivotal studies which took place in the USA and Europe. In turn, this could mean that patients will not have to undergo therapy as frequently. Two leading scientific centres in Austria participated in the pivotal studies, namely the University Eye Clinic of Vienna and the Medical University Eye Clinic in Graz, thus contributing to the further development of the substance. The Novartis sites in Kundl/Schattenau, Tyrol as well as the plant in Unterach am Attersee in Upper Austria also belong to the company's global network of research and development centres.

Here you can find out more about life sciences in Austria.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Investment Opportunities for Electronics Companies in Austria - Carinthia

    08.07.2020 / 2:30 pm IST, Online, Webinar

  • BIOMEDevice Boston 2020

    16. - 17.09.2020, Boston, USA

Austria Map

Find the perfect location for your company

Inspite of higher labor costs, the productivity of Siemens Villach is comparable to other Siemens susidiaries in Japan or the USA.

Siemens Austria

Logo
More testimonials

news from the business location Austria

Austria registers more patents than ever before

Austrian companies and researchers registered 2.341 new patents at the European Patent Office (EPO) in 2019. Over the last five years the number of Austrian patent applications increased consistently.

Concerning Facebook and LinkedIn: Austrian companies in the social media jungle

A growing number of companies are relying on social media to inform customers, open up new target groups and identify suitable employees. Firms are increasingly investing in Facebook and other social media as each year passes, However, at the same time the continuous further development and establishment of networks are also leading to uncertainties about the right way of handling these platforms.

More news All blog posts